Medistim Delivers Best Quarter Ever

Medistim delivers its best quarter ever and sales ended at MNOK 66.1 (MNOK 52.2), a growth of 26.6 %. Sales for 2014 ended at MNOK 214.8 (MNOK 191.0), a growth of 12.5 %. The atrong development in the US continued with a 62 % growth in sales for the quarter. For 2014 sales in the US increased with 23%. Operating profit (EBIT) for the quarter ended
at MNOK 14.5 (MNOK 9.0). Operating profit for 2014 ended at MNOK 43.4 (MNOK 35.6). Cashflow is strong in 2014 and cash by year end was 49.5 MNOK (MNOK 19.8.). Medistim launched its new product MiraQâ„¢ Cardiac in Europe during the quarter. The Board will to the general assembly suggest a dividend of NOK 1,40 per share (NOK 0.80).

PDF – Q4 presentation 2014

PDF – 4 quarter 2014